backtop


Print 9 comment(s) - last by dailyjohn.. on Nov 24 at 7:17 PM


  (Source: scientificamerican.com)
This could one day halt other immune-related diseases like Type 1 diabetes

A new method in the realm of nanotechnology has reset the immune system response in mice with multiple sclerosis (MS), which could one day halt other immune-related diseases like Type 1 diabetes. 

A team of researchers from Northwestern University, which was led by Stephen Miller and Lonnie Shea, were able to use nanoparticles to trick the immune system into not attacking myelin, which is a membrane that the immune system destroys to cause MS in patients. 

MS is diagnosed when myelin, a membrane that insulates nerve cells in the spinal cord, brain and optic nerve, is destroyed by the immune system. When myelin is attacked and destroyed, electrical signals cannot travel correctly, and this can lead to limb numbness and paralysis. 

Current treatments for MS include suppressing the entire immune system so that it cannot attack myelin. However, shutting down immune response means that the patient's body is more susceptible to infections and even cancer. 

The new method employed by the Northwestern researchers doesn't suppress the immune response, but rather tricks it into thinking that myelin is a normal part of the immune system. Hence, it doesn't attack the camouflaged membrane. 

This is how it works: myelin antigens are attached to nanoparticles, where the nanoparticles are made up of a polymer called Poly(lactide-co-gycolide), or PLG. PLG is made up of glycolin acid and lactic acid, which are natural metabolites in the human body. Also, PLG is already FDA-approved. 

These nanoparticles with myelin antigens were injected into mice -- the spleen, to be exact. Here, blood is filtered and aging or dying blood cells are tossed out. The nanoparticles were absorbed by immune cells called macrophages, and the antigens were shown on the cell surface. The immune system saw them as regular blood cells, and halted any attack. 

According to results, the team was able to prevent future relapses for up to 100 days.

"This is a highly significant breakthrough in translational immunotherapy," said Miller. "The beauty of this new technology is it can be used in many immune-related diseases. We simply change the antigen that's delivered. The holy grail is to develop a therapy that is specific to the pathological immune response, in this case the body attacking myelin. Our approach resets the immune system so it no longer attacks myelin but leaves the function of the normal immune system intact."

Source: Science Daily



Comments     Threshold


This article is over a month old, voting and posting comments is disabled

FIRST!
By BrotherPointy on 11/20/2012 7:45:39 AM , Rating: 2
Well that is awesome, now let's hope it works the same on humans and most importantly, if so, actually makes it to the market..




RE: FIRST!
By geddarkstorm on 11/20/2012 12:51:27 PM , Rating: 5
Thankfully, it should, on both accounts.

There are already phase II human trials using this technique but with white blood cells as the vehicle rather than nanoparticles. That has a lot of harvesting issues and expensive difficulties that the nanoparticles solve handedly. So, the tolerance systems being activated in the spleen exist the same in humans and mice so far as we've seen (it's a highly conserved system throughout the mammalian branch, so no surprise).

And then the nanoparticles themselves are just made out of two metabolites your body naturally makes, and is already used for biodegradable sutures, which have been FDA approved for a long time.

So, everything is looking marvelous for this new technology: proven indirectly, already FDA approved, and successful in mice. It should get a fast track to humans, and immediately eclipses the white blood cell therapies that are in the works.

This is the holy grail of immune system modulation. And best yet? We can use this for -any- autoimmune disease where we know the antigens. Rheumatoid arthritis, eczema, lupus, type I diabetes, maybe even Parkinson's, if that's ultimately caused by the immune system as some research suggests.


"We’re Apple. We don’t wear suits. We don’t even own suits." -- Apple CEO Steve Jobs














botimage
Copyright 2014 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki